Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes;Predicción de las reducciones en la dosis de warfarina para pacientes Puertorriqueños basado en los genotipos combinados de CYP2C9 y VKORC1

Annals of Pharmacotherapy

Volumn 46, Issue 2, 2012, Pages 208-218

  Valentin, Isa Ivette ^a   Vazquez, Joan ^a   Rivera Miranda, Giselle ^a   Seip, Richard L ^b   Velez, Meredith ^a   Kocherla, Mohan ^b   Bogaard, Kali ^b   Cruz Gonzalez, Iadelisse ^a   Cadilla, Carmen L ^c   Renta, Jessica Y ^c   Felliu, Juan F ^d   Ramos, Alga S ^a   Alejandro Cowan, Yirelia ^a   Gorowski, Krystyna ^b   Ruaño, Gualberto ^b   Duconge, Jorge ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b HARTFORD HOSPITAL   (United States)

^c UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^d Veterans Affairs Caribbean Healthcare System   (Puerto Rico)

Author keywords

CYP2C9; Genotyping; Pharmacogenomics; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE SUBUNIT C1; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; AORTOBIFEMORAL BYPASS; ARTICLE; BLOOD SAMPLING; BYPASS SURGERY; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VALVE BIOPROSTHESIS; HEART VALVE REPLACEMENT; HETEROZYGOTE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY DIAGNOSIS; LOSS OF FUNCTION MUTATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PUERTO RICO; STROKE; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PUERTO RICO; WARFARIN;

EID: 84857011893     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q190     Document Type: Article

References (58)

1. Lakshminarayan K, Solid CA, Collins AJ, et al. Atrial fibrillation and stroke in the general Medicare population: a 10-year perspective (1992-2002). Stroke 2006;37:1969-74.
2. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:204S-33S.
3. IMS Institute for Healthcare Informatics, April 2011. The use of medicines in the United States: review of 2010. www.imshealth.com/ deployedfiles/ imshealth/Global/Content/IMS%20Institute/Static%20File/IHII_UseOf Med_report.pdf (accessed 2011 May 14).
4. Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-rationale and perspectives. Thromb Res 2007;120:1-10.
5. Wadelius M. Point: use of pharmacogenetics in guiding treatment with warfarin. Clin Chem 2009;55:709-11.
6. Eby CS. Counterpoint: pharmacogenetic-based initial dosing of warfarin: not ready for prime time. Clin Chem 2009;55:712-4.
7. Couris R, Tataronis G, McCloskey W, et al. Dietary vitamin K variability affects international normalized ratio coagulation indices. Int J Vitam Nutr Res 2006;76:65-74.
8. Hylek EM. Oral anticoagulants: pharmacologic issues for use in the elderly. Clin Geriatr Med 2001;17:1-13.
9. Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 2002;36:1512-7. DOI 10.1345/aph.1C025
10. Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci 2009;30:375-86.
11. Seip RL, Duconge J, Ruaño G. Implementing genotype-guided antithrombotic therapy. Future Cardiol 2010;6:409-24.
12. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74.
13. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525-38.
14. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992;5:54-9.
15. Kaminsky LS, de Morais SM, Faletto MB, Dunbar DA, Goldstein JA. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 1993;43:234-9.
16. Kamali F, Pirmohamed M. The future prospects of pharmacogenetics in oral anticoagulation therapy. Br J Clin Pharmacol 2006;61:746-51.
17. Linder MW, Looney S, Adams JE III, et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis 2002; 14:227-32.
18. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
19. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72:702-10.
20. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 2005;93:700-5.
21. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-8.
22. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005;106:2329-33.
23. Reynolds KK, Valdes R Jr, Hartung BR, Linder MW. Individualizing warfarin therapy. Personalized Medicine 2007;4:11-31.
24. Zhu Y, Shennan M, Reynolds KK, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem 2007;53:1199-205.
25. Wu AH. Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics 2007;8:851-61.
26. Mushiroda T, Ohnishi Y, Saito S, et al. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet 2006;51:249-53.
27. Wadelius M, Sorlin K, Wallerman O, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004;4:40-8.
28. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005;5:262-70.
29. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007;121:23-34.
30. Gulseth M, Grice G, Dager W. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am J Health Syst Pharm 2009;66:123-33.
31. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 2004;14:539-47.
32. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004;427:537-41.
33. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature 2004;427:541-4.
34. Suttie JW. The biochemical basis of warfarin therapy. Adv Exp Med Biol 1987;214:3-16.
35. Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005;14:1745-51.
36. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352: 2285-93.
37. Klein TE, Altman RB, Eriksson N, et al. on behalf of the International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-64.
38. Gordon J, Merante F, Weiss S, Zastawny R. Pharmacogenetic P-450 screening using the Tag-It universal bead-based array platform. In: Wong SH, Linder MW, Valdes R, eds. Pharmacogenomics and proteomics: enabling the practice of personalized medicine. Washington, DC: AAC Press, 2006:363-86.
39. Ruaño G, Thompson PD, Villagra D, et al. High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing. Personalized Medicine 2008;5:225-32.
40. Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2009;112:1022-7.
41. Hughes AL, Welch R, Puri V, et al. Genome-wide SNP typing reveals signatures of population history. Genomics 2008;92:1-8.
42. Duconge J, Cadilla CL, Windemuth A, et al. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. Ethn Dis 2009;19:390-5.
43. Takahashi H, Wilkinson GR, Caraco Y, et al. Population differences in Swarfarin metabolism between CYP2C9 genotype-matched caucasian and Japanese patients. Clin Pharmacol Ther 2003;73:253-63.
44. Limdi NA, Arnett DK, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 2008;9:511-26.
45. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance doses of warfarin in Japanese, Caucasians and African Americans. Pharmacogenet Genomics 2006;16:101-10.
46. Yasar U, Eliasson E, Dahl ML, et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999;254:628-31.
47. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54:1257-70.
48. Loebstein R, Yonath H, Peleg D, et al. Inter-individual variability in sensitivity to warfarin-nature or nurture? Clin Pharmacol Ther 2001;70: 159-64.
49. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41:815-50.
50. Marsh S, King CR, Porche-Sorbet RM, Scott-Horton TJ, Eby CS. Population variation in VKORC1 haplotype structure. J Thromb Haemost 2006;4:473-4.
51. Llerena A, Dorado P, O'Kirwan F, Jepson R, Licinio J, Wong ML. Lower frequency of CYP2C9*2 in Mexican Americans compared with Spaniards. Pharmacogenomics 2004;4:403-6.
52. Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2007;83:312-20.
53. Perini JA, Petzl-Erler ML, Tsuneto LT, Suarez-Kurtz G. VKORC1 polymorphisms in Amerindian populations of Brazil. Pharmacogenomics 2008;9:1623-9.
54. Wu AHB, Wang P, Haller C, Drake K, Linder M, Valdes R Jr. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008;9:169-78.
55. Product information. Coumadin (warfarin). Princeton, NJ: Bristol-Myers Squibb Pharma Company, January 2010 (revision). www.accessdata.fda. gov/drugsatfda_docs/Label/2010/009218s108lbl.pdf (accessed 2010 Mar 9).
56. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with non-valvular atrial fibrillation. Ann Intern Med 2009;150:73-83.
57. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96.
58. Ruaño G, Duconge J, Windemuth A, et al. Physiogenomic analysis of the Puerto Rican population. Pharmacogenomics 2009;10:565-77.